145 related articles for article (PubMed ID: 21824090)
1. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
2. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
Assi HH; Paran C; VanderVeen N; Savakus J; Doherty R; Petruzzella E; Hoeschele JD; Appelman H; Raptis L; Mikkelsen T; Lowenstein PR; Castro MG
J Pharmacol Exp Ther; 2014 Jun; 349(3):458-69. PubMed ID: 24696041
[TBL] [Abstract][Full Text] [Related]
3. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.
Chen H; Bian A; Yang LF; Yin X; Wang J; Ti C; Miao Y; Peng S; Xu S; Liu M; Qiu WW; Yi Z
Oncogene; 2021 Feb; 40(8):1440-1457. PubMed ID: 33420372
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
5. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y; Dong Z; Liu K
J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
[TBL] [Abstract][Full Text] [Related]
6. Targeting STAT3 in Cancer Immunotherapy.
Zou S; Tong Q; Liu B; Huang W; Tian Y; Fu X
Mol Cancer; 2020 Sep; 19(1):145. PubMed ID: 32972405
[TBL] [Abstract][Full Text] [Related]
7. Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety.
Wang KN; Zhou K; Zhong NN; Cao LM; Li ZZ; Xiao Y; Wang GR; Huo FY; Zhou JJ; Liu B; Bu LL
Life Sci; 2024 Jun; 346():122635. PubMed ID: 38615745
[TBL] [Abstract][Full Text] [Related]
8. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein.
Fletcher S; Turkson J; Gunning PT
ChemMedChem; 2008 Aug; 3(8):1159-68. PubMed ID: 18683176
[No Abstract] [Full Text] [Related]
9. Disruption of transcriptionally active Stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities.
Fletcher S; Singh J; Zhang X; Yue P; Page BD; Sharmeen S; Shahani VM; Zhao W; Schimmer AD; Turkson J; Gunning PT
Chembiochem; 2009 Aug; 10(12):1959-64. PubMed ID: 19644994
[No Abstract] [Full Text] [Related]
10. The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase.
Heppler LN; Attarha S; Persaud R; Brown JI; Wang P; Petrova B; Tošić I; Burton FB; Flamand Y; Walker SR; Yeh JE; Zubarev RA; Gaetani M; Kanarek N; Page BDG; Frank DA
J Biol Chem; 2022 Feb; 298(2):101531. PubMed ID: 34953855
[TBL] [Abstract][Full Text] [Related]
11. Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides.
Shiah JV; Grandis JR; Johnson DE
Mol Cancer Ther; 2021 Feb; 20(2):219-228. PubMed ID: 33203730
[TBL] [Abstract][Full Text] [Related]
12. Transcription factors and chromatin proteins as therapeutic targets in cancer.
Johnston SJ; Carroll JS
Biochim Biophys Acta; 2015 Apr; 1855(2):183-92. PubMed ID: 25721328
[TBL] [Abstract][Full Text] [Related]
13. Azetidine ring, salicylic acid, and salicylic acid bioisosteres as determinants of the binding characteristics of novel potent compounds to Stat3.
Chen Y; Zhai N; Zhu Y; Yue P; Verma N; Brotherton-Pleiss C; Fu W; Nakamura K; Chen W; Kawakami J; Murali R; Tius MA; Lopez-Tapia F; Turkson J
Bioorg Med Chem Lett; 2024 Jan; 97():129565. PubMed ID: 38008341
[No Abstract] [Full Text] [Related]
14. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review).
Wang X; Crowe PJ; Goldstein D; Yang JL
Int J Oncol; 2012 Oct; 41(4):1181-91. PubMed ID: 22842992
[TBL] [Abstract][Full Text] [Related]
15. Revisiting STAT3 signalling in cancer: new and unexpected biological functions.
Yu H; Lee H; Herrmann A; Buettner R; Jove R
Nat Rev Cancer; 2014 Nov; 14(11):736-46. PubMed ID: 25342631
[TBL] [Abstract][Full Text] [Related]
16. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
17. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies.
Wong AL; Soo RA; Tan DS; Lee SC; Lim JS; Marban PC; Kong LR; Lee YJ; Wang LZ; Thuya WL; Soong R; Yee MQ; Chin TM; Cordero MT; Asuncion BR; Pang B; Pervaiz S; Hirpara JL; Sinha A; Xu WW; Yuasa M; Tsunoda T; Motoyama M; Yamauchi T; Goh BC
Ann Oncol; 2015 May; 26(5):998-1005. PubMed ID: 25609248
[TBL] [Abstract][Full Text] [Related]
18. The role of STAT3 signaling in mediating tumor resistance to cancer therapy.
Tan FH; Putoczki TL; Stylli SS; Luwor RB
Curr Drug Targets; 2014; 15(14):1341-53. PubMed ID: 25410411
[TBL] [Abstract][Full Text] [Related]
19. Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention.
Xiong A; Yang Z; Shen Y; Zhou J; Shen Q
Cancers (Basel); 2014 Apr; 6(2):926-57. PubMed ID: 24743778
[TBL] [Abstract][Full Text] [Related]
20. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
